Navigation Links
Max Planck Innovation awards license for actin marker LifeAct
Date:7/26/2010

Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, awards an exclusive license for LifeAct to ibidi GmbH, a provider of cell analysis products, located in Martinsried near Munich. The novel peptide allows for actin, an important protein, to be made visible in living cells without disturbing the actin dependent processes. Therefore, cells as well as the development of various diseases can be better researched.

All higher cells depend on their cytoskeleton. This extremely flexible and highly dynamic structure gives the cells its shape, but is also an essential component in cell division as well as other fundamental processes of life. As a structural protein, actin is a component of the cytoskeleton, which can form elongated filaments that are used as supply routes for molecular loads in the cell among other things. Thereby, actin plays an important role in a wide array of functions such as in the development of organs and the movement of cells. Defects in the cytoskeleton are associated with various diseases such as polycystic kidney diseases and invasive tumors. Thus, the study of the cytoskeleton and in particular the study of actin is a priority in the biomedical research.

In the past, markers were available that allowed visualization of actin, but also interfered with its activity. Whereas the actin marker LifeAct, now licensed by ibidi, attaches itself to the structural protein without limiting its function. LifeAct, only 17 amino-acids long, is linked to a fluorescent dye, which makes it possible to follow the development and movement in living cells. The marker has already been used successfully in yeast cells, kidney cells, white blood cells, neuron and a variety of other cell types and tissues. A research team led by the biologists Dr. Roland Wedlich-Sldner and Dr. Michael Sixt from the Max Planck Institute for Biochemistry developed the marker. In future, ibidi will offer the peptide in various products for biological analysis. Even pathological processes where actin is involved could be decoded.

"LifeAct fits perfectly into our product portfolio with cell microscopy, immunofluorescence and cell based assays" emphasizes Dr. Valentin Kahl, founder and CEO of ibidi. "With help of the marker, our customers can visualize and quantify the movement of cells. The new technology will be of great benefit, especially in studies of angiogenesis (the formation of blood vessels), but also in oncology, neurology, and immunology." Moreover, Dr. Mareike Gritz, patent and license manager at Max Planck Innovation, sees a great advantage in the proximity of Max Planck Institute for Biochemistry and Neurobiology to ibidi GmbH in Martinsried: " The mutual support and uncomplicated communication should ensure a close cooperation and hence a rapid market implementation of LifeAct." This should benefit the researchers and product developers as well as the research community. Thus, LifeAct opens unprecedented opportunities to research actin as an essential component of life's fundamental processes.


'/>"/>

Contact: Markus Berninger, Max-Planck-Innovation GmbH
Markus.Berninger@max-planck-innovation.de
49-089-290-91930
Max-Planck-Gesellschaft
Source:Eurekalert  

Related biology news :

1. Innovation and current status of prostate cancer gene therapy featured in Human Gene Therapy
2. NY state the focus of Congressional hearing on how research and innovation fuel local economies
3. ACS Webinar focuses on green chemistry innovations and applications
4. Biotherapeutic Innovations on Display at AAPS National Biotechnology Conference
5. EPA awards more than $1 million to college teams for environmental innovation
6. Research & Entrepreneurship Day 2010: Engineering Innovation
7. Innovation in science
8. UT Southwesterns BioCenter driving biotech, medical innovation in North Texas
9. Oberthur Technologies Receives Product Innovation Award
10. Leaders from the National Academies gather to discuss engineering innovations in health care
11. Innovation boost to tackle climate change
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Max Planck Innovation awards license for actin marker LifeAct
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former senior ... the University of North Carolina Kenan-Flagler Business School effective June 27. ... Kenan-Flagler, with a focus on the school’s international efforts, leading classes and participating ...
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology: